+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Effects of Oxprenolol versus Propranolol on Myocardial Performance and Myocardial O 2 Consumption in Hypertensive Patients

      , ,


      S. Karger AG

      Oxprenolol, Propranolol, Myocardial O2 consumption, Systolic time interval

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The purpose of the study was to compare the effects of oxprenolol, a beta-adrenergic blocking agent with intrinsic sympathomimetic activity, to propranolol, a beta-blocker without intrinsic sympathomimetic activity, on myocardial performance and myocardial O<sub>2</sub> consumption (MVO<sub>2</sub>). Myocardial performance was reflected by the systolic time intervals (STI) and MVO<sub>2</sub> by the triple product of heart rate × left ventricular ejection time × systolic blood pressure (HR × LVET × SBP). The trial, a double-blind cross-over study, included 32 hypertensive patients, 17 males and 15 females, with a mean age of 50.9 years. The patients were divided into two groups: group A – 16 patients who were treated with effective antihypertensive doses of oxprenolol and diuretics (Esidrex K) for the first 8 weeks (period I) and with similar doses of propranolol and diuretics for the following 8 weeks (period II); Group B – the same number of patients who received the same drugs in the reverse order. All patients were examined during both periods at 2- and 3-week intervals, blood pressure and heart rate were recorded, and patients were provided with the appropriate study medication. At the end of periods I and II, myocardial function was assessed on the basis of STI, and MVO<sub>2</sub> was evaluated on the basis of the triple product of HR × LVET × SBP. Four measurements of STI and MVO<sub>2</sub> were carried out for each patient at the end of periods I and II: prior to intake of medication and 1½, 3 and 4½ h after intake of medication. The results of the study indicated in all four measurements a tendency for lower myocardial performance in both groups following propranolol treatment as compared to oxprenolol. This tendency was more marked on the third and fourth measurements, during which higher blood levels are expected, and was statistically significant on measurement IV (p < 0.001, t = 3.5 for the ratios PEP/LVET). A slight tendency for lower values of MVO<sub>2</sub> following the treatment with propranolol as compared to oxprenolol was obtained (measurement I: t = 2.04, p < 0.05; measurement IV: t = 1.56, p < 0.05). It can be concluded that treating hypertensive patients with propranolol is accompanied by a somewhat lower myocardial function and a tendency for lower MVO<sub>2</sub> as compared to treatment with oxprenolol. Treatment with oxprenolol seems, therefore, to be superior to propranolol in patients with impaired myocardial function.

          Related collections

          Author and article information

          S. Karger AG
          07 November 2008
          : 70
          : 4
          : 199-205
          Heart Institute, Asaf Harofe Hospital, Zerifin, and Sackler School of Medicine, Tel Aviv University, Israel
          173594 Cardiology 1983;70:199–205
          © 1983 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 7
          Original Paper


          Comment on this article